Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trabectedin versus dacarbazine in advanced liposarcoma or leiomyosarcoma
2016-000929-40Phase 3
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2016
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in Liposarcoma and leiomyosarcoma (LMS) comparing Trabectedin arm with Dacarbazine arm (2 arms). Primary endpoint: Overall survival.
02
Drugs
trabectedindacarbazine
03
Conditions
Liposarcomaleiomyosarcoma (LMS)
Beyond the preview
Go deeper on 2016-000929-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000929-40.